Analysts Set Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Price Target at $12.33

Shares of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) have been assigned a consensus rating of "Buy" from the six analysts that are presently covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $12.33.

A number of equities research analysts recently commented on the company. Canaccord Genuity Group reaffirmed a "buy" rating and set a $9.00 price objective on shares of Rani Therapeutics in a research note on Wednesday, February 26th. HC Wainwright restated a "buy" rating and set a $9.00 target price on shares of Rani Therapeutics in a report on Thursday, April 3rd.

Institutional Trading of Rani Therapeutics

Large investors have recently modified their holdings of the stock. Janney Montgomery Scott LLC acquired a new stake in Rani Therapeutics in the fourth quarter valued at approximately $37,000. Virtu Financial LLC acquired a new position in Rani Therapeutics during the fourth quarter worth $62,000. Insigneo Advisory Services LLC bought a new position in shares of Rani Therapeutics in the fourth quarter valued at $65,000. CWA Asset Management Group LLC acquired a new position in shares of Rani Therapeutics during the first quarter valued at about $105,000. Finally, Two Sigma Advisers LP bought a new stake in shares of Rani Therapeutics during the fourth quarter worth about $151,000. Institutional investors and hedge funds own 30.19% of the company's stock.

Rani Therapeutics Stock Down 0.9 %

Rani Therapeutics stock traded down $0.01 during mid-day trading on Thursday, hitting $1.09. The company's stock had a trading volume of 23,391 shares, compared to its average volume of 742,156. The company has a debt-to-equity ratio of 2.34, a current ratio of 1.60 and a quick ratio of 1.60. Rani Therapeutics has a 52-week low of $1.02 and a 52-week high of $7.88. The firm's 50 day moving average is $1.35 and its 200 day moving average is $1.66. The company has a market cap of $62.66 million, a PE ratio of -1.03 and a beta of 0.24.

Rani Therapeutics (NASDAQ:RANI - Get Free Report) last announced its earnings results on Monday, March 31st. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The company had revenue of $1.03 million during the quarter. On average, analysts anticipate that Rani Therapeutics will post -1.01 earnings per share for the current year.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.